Novartis reported CHF4.84B in EBITDA for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Alcon AG ALC:SW 484M 16M
Amgen AMGN:US $ 3228M 40M
AstraZeneca AZN:LN 2784M 588M
Bayer BAYN:GR € 2089M 946M
Biogen BIIB:US $ 991.8M 155.8M
Bristol Myers Squibb BMY:US $ 5712M 33M
Eli Lilly And LLY:US $ 2437.5M 639.8M
Fresenius FRE:GR € 1711M 31M
Fresenius Medical Care FME:GR € 886M 14.67M
Galapagos GLPG:NA € -70.14M 39.37M
Gilead Sciences GILD:US $ 4370M 1605M
GlaxoSmithKline GSK:LN 3660M 1034M
GRIFOLS GRF:SM € 330.18M 44.07M
H. Lundbeck A/S LUN:DC 933M 62M
Hikma Pharmaceutical HIK:LN 358M 9M
Johnson & Johnson JNJ:US $ 8192M 2043M
Lonza Group LONN:SW 847M 291M
Merck MRK:GR € 1551M 25M
Novartis NOVN:VX SF 4837M 65M
Novartis NVS:US $ 4837M 65M
Orion ORNBV:FH € 68.4M 13.6M
Pfizer PFE:US $ 10235M 2245M
Philips PHIA:NA € 754M 29M
Recordati REC:IM € 147.44M 2.75M
Regeneron Pharmaceuticals REGN:US $ 1920.4M 1497.9M